Invalidity dossier
US 9155705
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
Added 9/16/2026, 6:46:41 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 9,155,705 B2
Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation.
Assignee: Boehringer Ingelheim International GmbH (original and current assignee per the listing).
Key dates: Priority date 2008-04-03; filing date 2009-04-02; publication of US20110206766A1 on 2011-08-25; granted 2015-10-13. Status listed as Active with adjusted expiration 2030-05-21. These are the source's stated assumptions, not legal conclusions.
Application: US12/935,634. Inventors listed: Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, Takaaki Nishioka.
Purpose and plain-language scope: The title indicates the invention concerns combining a DPP-IV inhibitor with another antidiabetic agent, and tablet formulations of that combination, plus their use and a manufacturing process. The excerpt lists numerous chemical structures, including one (TTYUNRVFZJWXHB-MRXNPFEDSA-N) that is the only entry weighted in the description, plus about twenty other compounds also associated with the description, and a Markush-type formula: [1*]N1C(=O)C2=C(C(C#N)=C([2*])N2CC#CC)N(C)C1=O and variants. Classification codes cluster in A61K (medical preparations), including A61K31/522 (purine derivatives with oxo groups, e.g. xanthines), A61K45/06 (mixtures of active ingredients), and A61K47/18 (amines, amides, amino acids as formulation components), consistent with a combined oral tablet containing a DPP-IV inhibitor. Prior-art keywords supplied are "methyl," "pharmaceutical composition," "tablet," "dpp," and "composition according." The excerpt also lists Delaware District Court case links (1:20-cv-01153; 1:21-cv-00530; 1:24-cv-01091), noted here only as present in the source, not analyzed.
What the excerpt does not establish: It contains no claim text, no explicit identification of which named compound is the DPP-IV inhibitor or which is the "further antidiabetic agent," no dosages, ratios, excipients, or process steps, and no written description supporting specific claim scope. Litigation, ownership, validity, and prior art are outside this overview.
Generated 10/1/2026, 10:03:28 PM
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 9155705. The free-form analysis below may also discuss cases beyond this list.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.
Keep exploring
More patents asserted by Boehringer Ingelheim Pharmaceuticals Inc.
- US 9415016I'll search for authoritative information on US 9415016, including its claims and any 2026 CAFC docket activity. Let me look for the claim text of US 9415016 and any Federal Circuit activity. Let me try to retrieve the actual claim set…
- US 10022379Patent Overview — US 10022379 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Patent number / application: US 10022379 B2…
- US 11911388Patent Overview: US11911388B2 Title: Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug Assignee: Boehringer Ingelheim International GmbH Key dates: Priority…
- US 10973827Patent Overview: US10973827B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Patent number: US10973827B2 | Application: US16/676,643 |…
This patent in court (1)
1 tracked lawsuit name US 9155705.